CST7

CST7 encodes cystatin F, a cysteine protease inhibitor with restricted hematopoietic expression that regulates endolysosomal proteolytic activity, immune cell differentiation, and neuroinflammation. Intracellular cystatin F localizes to endosomal/lysosomal compartments where it directly inhibits cathepsins C, L, and S, thereby controlling proteolytic capacity during monocyte-to-macrophage differentiation under transcriptional regulation by C/EBPα and Runx2/G9a at the CST7 promoter (PMID:30033148, PMID:22389001, PMID:12423348). In microglia, RIPK1-dependent induction of Cst7 drives endolysosomal dysfunction that impairs amyloid-β clearance and contributes to the disease-associated microglia (DAM) state, with sex-dependent effects on lysosomal burden and phagocytic capacity in Alzheimer's disease models (PMID:28904096, PMID:38085657). In the CNS, cystatin F limits T cell–mediated neuroinflammation and promotes remyelination by suppressing chemokine (Cxcl9/Cxcl10) and cytotoxic effector gene expression, and in peripheral immunity it is upregulated in neutrophils during acute inflammation where it influences NET formation and MMP9-high neutrophil states (PMID:38879499, PMID:40151877).

1. 2000 Medium

   Genomic characterization of CST7 revealed a four-exon gene at 20p11.21 with a promoter architecture lacking housekeeping elements, establishing the structural basis for its restricted hematopoietic expression pattern.

   Evidence FISH mapping and computational promoter analysis of human and mouse CST7 loci

   PMID:10945474

   Open questions at the time

   • No functional promoter assays performed
   • Expression restriction inferred from promoter structure rather than demonstrated experimentally across tissues
2. 2002 High

   Demonstration that cystatin F is partially retained intracellularly in granular cytoplasmic compartments (not ER) and is transcriptionally regulated by a C/EBPα binding site in its promoter resolved how this secreted-family member achieves intracellular function and lineage-restricted expression.

   Evidence Immunocytochemistry, immunofluorescence double-staining, promoter analysis, and differentiation assays in U937 promyeloid cells

   PMID:12423348

   Open questions at the time

   • Identity of the granular compartment (endosome vs. lysosome) not resolved
   • Mechanism of intracellular retention unknown
3. 2012 High

   Identification of Runx2 and its cofactor G9a as transcriptional regulators of CST7 in prostate cancer cells revealed a second transcriptional axis controlling CST7 expression, independent of C/EBPα, and showed that G9a's role is scaffold-based rather than catalytic.

   Evidence Reciprocal co-IP, GST pulldown, ChIP, siRNA knockdown, and reporter assays in C4-2B cells

   PMID:22389001

   Open questions at the time

   • Runx2/G9a regulation of CST7 not confirmed in hematopoietic cells
   • Whether Runx2-driven CST7 expression has functional consequences for protease inhibition not tested
4. 2017 High

   Two studies established Cst7 as a signature gene of disease-associated microglia: RIPK1 kinase-dependent induction of Cst7 impairs lysosomal degradation and Aβ clearance in AD models, while Cst7 is the most strongly upregulated transcript in early prion disease, positioning cystatin F as a central node in microglial endolysosomal dysfunction across neurodegeneration.

   Evidence Pharmacological/genetic RIPK1 inhibition in APP/PS1 mice with lysosomal assays; global transcriptional profiling and protein quantification across multiple prion mouse models

   PMID:28178353 PMID:28904096

   Open questions at the time

   • Whether Cst7 induction is causally required for lysosomal impairment vs. a marker was not resolved in these studies
   • Upstream signal linking prion infection to Cst7 induction unknown
5. 2018 High

   ChIP confirmed direct C/EBPα binding at the CST7 promoter in vivo, and co-IP/PLA identified cathepsins C, L, and S as the principal intracellular targets of cystatin F, establishing the complete transcription-to-target axis during monocyte differentiation.

   Evidence ChIP, co-immunoprecipitation, proximity ligation assay, and confocal microscopy in U937 and HL-60 cells during PMA-induced differentiation

   PMID:30033148

   Open questions at the time

   • Relative contribution of each cathepsin to the differentiation phenotype not dissected
   • Whether cathepsin inhibition is the sole mechanism of cystatin F's biological effects not addressed
6. 2021 Medium

   Multi-cohort analysis revealed that CST7 upregulation during acute inflammation is neutrophil-specific (not NK or CD8+ T cell) and is driven by an unidentified endogenous serum factor rather than by known microbial products or cytokines.

   Evidence Transcriptome analysis across 43 datasets, cell-type deconvolution, and negative stimulation experiments with microbial products and cytokines

   PMID:33868254

   Open questions at the time

   • The endogenous serum factor inducing neutrophil CST7 remains unidentified
   • Functional consequence of neutrophil CST7 upregulation during inflammation not tested
7. 2023 High

   Genetic loss-of-function of Cst7 in an amyloid AD model demonstrated that cystatin F functionally regulates endolysosomal activity, phagocytosis, and inflammatory state of microglia in a sex-dependent manner, resolving whether Cst7 is merely a DAM marker or an active driver.

   Evidence Cst7 knockout crossed with App amyloidosis model; in vivo amyloid and lysosomal burden, in vitro phagocytosis, transcriptomics with sex stratification

   PMID:38085657

   Open questions at the time

   • Molecular basis for sex dimorphism in Cst7 function unknown
   • Which cathepsin target(s) mediate the sex-specific phenotypes not determined
8. 2024 High

   Cst7 knockout in a viral CNS infection model showed that cystatin F limits neuroinflammation and demyelination by suppressing T cell chemoattractant and cytotoxic gene programs, establishing a CNS-protective, remyelination-promoting role independent of direct antiviral activity.

   Evidence Cst7−/− mice with intracranial JHMV infection; scRNA-seq, flow cytometry, histology, electron microscopy with g-ratio analysis

   PMID:38879499

   Open questions at the time

   • Whether cystatin F acts cell-autonomously in microglia or also in infiltrating immune cells not resolved
   • Mechanism linking cathepsin inhibition to chemokine suppression not established
9. 2025 Medium

   In myocardial ischemia/reperfusion, SPI1-driven CST7 expression promotes MMP9-high neutrophil states and NET formation, extending cystatin F's functional role beyond cathepsin inhibition to regulation of neutrophil effector programs in sterile inflammation.

   Evidence Single-cell transcriptomics, SPI1/CST7 targeting, NET formation assays, and in vivo MI/RI model

   PMID:40151877

   Open questions at the time

   • Direct molecular mechanism linking CST7 to MMP9 expression and NET formation not delineated
   • Whether CST7's protease inhibitor activity is required for this function unknown

• The molecular mechanism by which cystatin F's cathepsin-inhibitory activity translates into regulation of chemokine expression, T cell programs, and NET formation remains unresolved, as does the basis for its sex-dependent effects in neurodegeneration.
• No structural model of cystatin F–cathepsin complexes in endolysosomes
• Endogenous serum factor inducing neutrophil CST7 during inflammation unidentified
• Mechanism of sex dimorphism in Cst7 microglial function unexplained